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Abstract: Background: The prognostic value of erythrocyte levels of n-6 fatty acids (FAs) for total
mortality and cardiovascular disease (CVD) outcomes remains an open question. Methods: We
examined cardiovascular (CV) outcomes and death in 2500 individuals in the Framingham Heart
Study Offspring cohort without prevalent CVD (mean age 66 years, 57% women) as a function of
baseline levels of different length n-6 FAs (18 carbon, 20 carbon, and 22 carbon) in the erythrocyte
membranes. Clinical outcomes were monitored for up to 9.5 years (median follow up, 7.26 years).
Cox proportional hazards models were adjusted for a variety of demographic characteristics, clinical
status, and red blood cell (RBC) n-6 and long chain n-3 FA content. Results: There were 245 CV
events, 119 coronary heart disease (CHD) events, 105 ischemic strokes, 58 CVD deaths, and 350 deaths
from all causes. Few associations between either mortality or CVD outcomes were observed for
n-6 FAs, with those that were observed becoming non-significant after adjusting for n-3 FA levels.
Conclusions: Higher circulating levels of marine n-3 FA levels are associated with reduced risk for
incident CVD and ischemic stroke and for death from CHD and all-causes; however, in the same
sample little evidence exists for association with n-6 FAs. Further work is needed to identify a full
profile of FAs associated with cardiovascular risk and mortality.
Keywords: epidemiology; prospective cohort study; n-6 fatty acids; n-3 fatty acids; linoleic acid;
arachidonic acid
1. Introduction
The roles of n-3 and/or n-6 polyunsaturated fatty acids (PUFAs) in health and disease are
controversial. Whereas most studies have reported that higher circulating levels of the long-chain
n-3 PUFAs (i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are protective against
cardiovascular disease (CVD) and premature death [1], the story is not as clear for the n-6 PUFAs.
Previous studies have reported that higher intakes of linoleic acid (LA) and higher circulating levels
of arachidonic acid (AA) are associated with cardiovascular (CV) benefit [1,2]. In addition, LA blood
levels are inversely associated with risk for type 2 diabetes mellitus [3]. Nevertheless, some warn
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that current intakes (and thus blood levels) of the n-6 PUFAs, especially these two major fatty acids
(FAs) in the n-6 family, are dangerous [4,5]. The proposed mechanism of harm is via increased
inflammation, driven by the conversion of AA into pro-inflammatory/pro-thrombotic eicosanoids
such as prostaglandin E2, thromboxane A2, and leukotriene B4 [6]. Accordingly, ratios like n-6:n-3 [7]
or AA:EPA [8] have been promoted as better summary metrics of PUFA status than either family alone.
This perspective has, however, been criticized on both theoretical [9–12] and evidential [13–15] bases.
In a previous report from the Framingham Offspring cohort, we examined relations between red
blood cell (RBC) n-3 FAs, specifically EPA and DHA (the sum of which is called the omega-3 index [16])
and risk for CVD and total mortality [17]. In this follow-up analyses, we focus on the n-6 FA family
and their relations with these outcomes.
2. Materials and Methods
2.1. Methods
The Framingham Heart Study is a longitudinal community-based cohort study that was initiated
in 1948. The selection criteria for the Framingham Offspring Cohort and the Framingham Omni Cohort
have previously been described [18,19]. Briefly, adult children of the original cohort were recruited
in 1971 into the Framingham Offspring Cohort. We evaluated Framingham Offspring participants
(n = 3021) who attended their eighth examination cycle (2005–2008). Participants were excluded in
hierarchical order if they were missing RBC fatty acid measurements or clinical covariates (n = 122),
or having prevalent cardiovascular disease (e.g., nonfatal coronary heart disease (CHD) or stroke;
n = 350), leaving n = 2500 for this analysis. The study protocol was approved by the Institutional Review
Board of the Boston University Medical Center. Informed consent was provided by all participants.
2.2. Covariates and Mortality Outcomes
We considered seventeen primary baseline demographic and cardiovascular risk covariates: sex,
age, body mass index (BMI), marital status, education level, employment status, health insurance
status, regular aspirin use, prevalent hypertensive status, use of cholesterol medication, prevalent
diabetes, alcohol consumption, smoking status, metabolic equivalent (METS), total to high-density
lipoprotein (HDL) cholesterol ratio, systolic blood pressure and C-reactive protein. Seven endpoints
were examined: four mortality-related outcomes ((1) any mortality, (2) CVD mortality (CHD death or
sudden cardiac death), (3) cancer mortality, or (4) death from non-CVD or cancer causes) and three
cardio-vascular related outcomes ((1) total stroke (any fatal or non-fatal ischemic stroke), (2) total CHD
(fatal or non-fatal myocardial infarction (MI), or CHD death or sudden cardiac death), and (3) total
CVD (any stroke, CHD or CHD mortality)). We focused our analyses on seven RBC FAs from the
n-6 family: 18:2n6 (linoleic acid, LA), 18:3n6 (gamma-linolenic acid, GLA), 20:2n6 (eicosadienoic acid,
EDA), 20:3n6 (dihomo-gamma linolenic acid, DGLA), 20:4n6 (arachidonic acid, AA), 22:4n6 (adrenic
acid, ADA) and 22:5n6 (docosapentaenoic acid, DPA n-6). In some analyses, we adjusted for the
omega-3 index (EPA + DHA).
2.3. RBC Fatty Acid Analysis
Blood was drawn after a 10–12 h fast into an EDTA tube, and RBCs were separated from plasma
by centrifugation. The RBC fraction was frozen at −80 ◦C immediately after collection. RBC fatty acid
composition was determined as described previously [20]. Briefly, RBCs were incubated at 100 ◦C with
boron trifluoride-methanol and hexane to generate fatty acid methyl esters that were then analyzed by
gas chromatography with flame ionization detection. The coefficients of variation for the seven n-6
FAs measured were <3% for 18:2n6, 20:3n6, 20:4n6, and 22:4n6; 7% for 22:5n6; 11% for 20:2n6 and 21%
for 18:3n6.
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2.4. Statistical Analysis
Description of sample characteristics was conducted using standard statistical metrics (e.g., means,
SDs, correlations). Hazard ratios were estimated using the survival package in R [21]. Primary analyses
predicted incident clinical outcomes (date of event (CVD or death) or date of censoring) by groups
of n-6 FAs (the 18-carbon, 20-carbon, and 22-carbon moities), with follow-up analyses adjusting for a
variety of demographic covariates, and finally for the omega-3 index. Secondary analyses explored the
relationship between event risk and n-6 FA levels by quintiles, individual omega-6 FA levels, and the
sum of all omega-6 FAs. All analyses used two-sided tests at the 0.05 significance level.
3. Results
3.1. Cohort Description
The Framingham Offspring study consists of 2500 individuals for whom FAs, clinical outcomes,
and demographic covariates were available, and who also did not have prevalent CVD at baseline.
At baseline, the average age was 66 and the sample contained slightly more females (57%) than males
(43%). The sample was fairly well educated (over two-thirds of the sample had at least some college
education), with approximately half of the sample employed and the majority of the remainder having
retired. Most (88%) of the sample had insurance at baseline and the distribution of cardiometabolic
traits followed expected distributions, with approximately 40% of the sample using aspirin regularly,
with similar numbers with prevalent hypertension, and high cholesterol. Rates of prevalent diabetes
was lower (13%). The majority of the sample periodically consumed alcohol, and the vast majority
(over 90%) were nonsmokers. Table 1 provides a complete overview of the demographic profile of the
sample. Supplemental Table S1 illustrates the correlation between and among the major n-3 and n-6
fatty acids in this sample. While correlations are generally higher within the n-3 or n-6 fatty acids than
between, this is not always the case (e.g., moderate negative correlations between both 20:2n6, 20:3n6,
and 20:4n6 levels). Supplemental Table S2 illustrates the number of events present in the sample with
350 of the participants having died from any cause during the course of the study, but only 58 of those
deaths were attributable to CVD. The maximum time to follow-up was approximately 9 years.
3.2. Omega-6 Fatty Acids and Mortality and Cardiovascular Disease Risk
Across all three classes of n-6 FAs (18-carbon, 20-carbon and 22-carbon) little evidence of
association with cardiovascular outcomes or mortality was observed. In unadjusted analyses,
the 18-carbon n-6′s showed an association with reduced risk of CVD and other (non-CVD, non-cancer)
mortality, however, these associations became non-significant after adjusting for demographic variables
(Table 2a). No associations were detected before or after evaluating 20-carbon n-6s (Table 2b).
While 22-carbon n-6′s showed some evidence of positive association with Total CVD, CHD, and
stroke risk after adjusting for demographic covariates, all of these associations became non-significant
after also adjusting for the omega-3 index (Table 2c). Notably, the omega-3 index remained significant
in many of the models for CVD event risk and CVD, non-cancer/non-CVD and all-cause mortality
(Table 2a–c; Figure 1).
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Table 1. Demographic overview (n = 2500). METS: metabolic equivalent.
Variable
Died
(n = 350)
Still Living
(n = 2150) Total
p-Value for Difference
(Chi-Squared or t-Test)
% (n) or Mean (SD) % (n) or Mean (SD) % (n) or Mean (SD)
Sex
Male 52.9% (185) 41.5% (893) 43.1% (1078)
<0.001Female 47.1% (165) 58.5% (1257) 56.9% (1422)
Age 72.9 (8.6) 64.4 (8.2) 65.56 (8.76) <0.001
Body Mass Index (BMI) 27.9 (5.9) 28.3 (5.4) 28.2 (5.4) <0.001
Marital Status
Single/Never Married 4.3% (15) 6.7% (144) 6.4% (159)
<0.001
Married 63.7% (223) 70.7% (1519) 69.7% (1742)
Separated/Divorced 12.0% (42) 12.7% (273) 12.6% (315)
Widowed 18.3% (64) 9.4% (203) 10.7% (267)
Education
Some High School (HS) or less 6.0% (21) 2.4% (51) 2.9% (72)
<0.001
HS graduate 33.7% (118) 24.8% (533) 26.0% (651)
Some college or vocational 22.9% (78) 21.9% (471) 22.0% (549)
College graduate 36.6% (128) 50.5% (1086) 48.6% (1214)
Employment
Employed 31.1% (109) 56.3% (1210) 52.8% (1319)
<0.001Disabled/unemployed 3.1% (11) 2.5% 53) 2.6% (64)
Retired 64.3% (225) 40.8% (877) 44.1% (1102)
Health insurance status
No insurance 2.3% (8) 1.9% (40) 1.9% (48)
0.053Insurance, but no prescription 11.4% (40) 8.4% (181) 8.8% (221)
Full insurance 84.0% (294) 88.7% (1906) 88.0% (2200)
Regular aspirin use 49.7% (174) 38.6% (830) 40.2% (1004) <0.001
Prevalent hypertension 57.1% (200) 42.2% (908) 44.3% (1108) <0.001
Cholesterol medication 41.4% (145) 36.9% (794) 37.6% (939) 0.06
Prevalent diabetes 22.3% (78) 11.6% (249) 13.1% (327) <0.001
Alcohol consumption
None 34.0% (119) 23.2% (499) 24.7% (618)
<0.001
<1 drink/day 36.0% (126) 50.7% (1089) 48.6% (1215)
1–2 drinks/day 22.6% (79) 20.2% (434) 20.5% (513)
>2 drinks/day 6.9% (24) 5.7% (123) 5.9% (147)
Smoking
Not current smoker 89.1% (312) 90.5% (1946) 90.3% (2258)
0.70Current 10.6% (37) 9.3% (200) 9.5% (237)
METS 4.7 (15.4) 3.3 (8.6) 3.5 (9.9) <0.001
Total to High-Density
Lipoprotein (HDL) cholesterol
ratio
3.5 (1.1) 3.5 (1.0) 3.5 (1.1) <0.001
Systolic Blood Pressure 133.6 (19.8) 128.2 (16.9) 129.0 (17.4) <0.001
C-reactive protein 4.9 (12.7) 3.0 (6.1) 3.3 (7.4) <0.001
Omega-3 index 0.054 (0.017) 0.056 (0.017) 0.0554 (0.0168) <0.001
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Table 2. Risk of events and mortality by n-6 fatty acid carbon chain length (n = 2500). (a) Eighteen-carbon n-6 fatty acids (18:2n6 + 18:3n6). (b) Twenty-carbon n-6 fatty
acids (20:2n6 + 20:3n6 + 20:4n6). (c) Twenty-two-carbon n-6 fatty acids (22:4n6 + 22:5n6).
(a)
Total Events Mortality
CVD CHD Stroke CVD Cancer Other Total
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
A. Unadjusted
<9.8% 18-carbon (n = 433) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
9.8%–10.7% (n = 488) 1.07 (0.71, 1.61) 1.30 (0.72, 2.35) 1.28 (0.67, 2.43) 1.14 (0.45, 2.89) 0.96 (0.58, 1.58) 0.56 (0.31, 1.02) 0.92 (0.64, 1.31)
10.7%–11.5% (n = 522) 1.05 (0.71, 1.57) 1.08 (0.59, 1.98) 1.33 (0.72, 2.43) 0.86 (0.33, 2.19) 0.81 (0.48, 1.36) 0.51 (0.29, 0.92) * 0.77 (0.54, 1.11)
11.5%–12.5% (n = 522) 0.74 (0.48, 1.13) 0.80 (0.42, 1.52) 0.70 (0.35, 1.38) 1.74 (0.71, 4.25) 0.56 (0.32, 1.00) 0.86 (0.53, 1.39) 0.94 (0.67, 1.31)
>12.5% (n = 535) 0.73 (0.48, 1.13) 1.01 (0.56, 1.81) 0.80 (0.39, 1.63) 0.57 (0.22, 1.53) 0.74 (0.43, 1.25) 0.52 (0.29, 0.93) * 0.74 (0.52, 1.06)
p-value for linear trend 0.032 * 0.45 0.15 0.26 0.08 0.17 0.14
B. Adjusted for demos
<9.8% 18-carbon (n = 433) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
9.8%–10.7% (n = 488) 1.28 (0.83, 1.95) 1.42 (0.76, 2.67) 1.46 (0.71, 3.00) 1.19 (0.48, 2.96) 1.09 (0.63, 1.88) 0.87 (0.47, 1.60) 1.21 (0.84, 1.73)
10.7%–11.5% (n = 522) 1.37 (0.90, 2.08) 1.38 (0.74, 2.56) 1.51 (0.77, 2.96) 1.12 (0.42, 2.97) 0.89 (0.49, 1.61) 0.83 (0.45, 1.56) 1.02 (0.69, 1.50)
11.5%–12.5% (n = 522) 0.78 (0.48, 1.27) 0.96 (0.46, 2.02) 0.72 (0.33, 1.61) 1.59 (0.67, 3.75) 0.65 (0.35, 1.20) 1.02 (0.58, 1.80) 0.99 (0.68, 1.44)
>12.5% (n = 535) 1.16 (0.72, 1.89) 1.53 (0.75, 3.13) 1.12 (0.52, 2.40) 0.96 (0.33, 2.80) 0.88 (0.47, 1.65) 0.62 (0.29, 1.33) 1.02 (0.68, 1.53)
p-value for linear trend 0.68 0.59 0.49 0.68 0.30 0.42 0.69
C. Adjusted for demos and O3I
<9.8% 18-carbon (n = 433) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
9.8%–10.7% (n = 488) 1.19 (0.78, 1.82) 1.32 (0.70, 2.49) 1.29 (0.62, 2.66) 1.08 (0.43, 2.73) 1.07 (0.62, 1.87) 0.74 (0.39, 1.41) 1.14 (0.79, 1.64)
10.7%–11.5% (n = 522) 1.28 (0.84, 1.95) 1.28 (0.69, 2.38) 1.34 (0.67, 2.65) 1.04 (0.38, 2.78) 0.87 (0.47, 1.61) 0.71 (0.38, 1.34) 0.95 (0.64, 1.41)
11.5%–12.5% (n = 522) 0.71 (0.44, 1.16) 0.86 (0.41, 1.79) 0.62 (0.28, 1.39) 1.49 (0.65, 3.44) 0.64 (0.34, 1.19) 0.83 (0.46, 1.50) 0.92 (0.63, 1.34)
>12.5% (n = 535) 1.03 (0.63, 1.67) 1.32 (0.64, 2.73) 0.93 (0.43, 2.03) 0.78 (0.26, 2.34) 0.86 (0.45, 1.63) 0.52 (0.24, 1.11) 0.92 (0.61, 1.40)
p-value for linear trend 0.34 0.92 0.23 0.87 0.28 0.18 0.38
p-value for omega-3 0.005 ** 0.034 * 0.004 ** 0.10 0.70 0.004 ** 0.011
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; O3I, Omega-3 Index. * p < 0.05; ** p < 0.01. All significant hazard ratios/p-values are
shown in bold italics. A. Unadjusted model, B. Adjusted for all variables in Table 1 except history of CVD, C. Adjusted for omega-3 index and all variables in Table 1 except history of CVD.
Quintiles for 18-carbon n-6 fatty acids are shown in the left-most column. For example, 9.8%–10.7% means that the second quintile for RBC 18-carbon n-6 fatty acids are individuals for
whom between 9.8 and 10.7% of all RBC fatty acids are 18-carbon n-6 fatty acids.
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Table 2. Cont.
(b)
Total Events Mortality
CVD CHD Stroke CVD Cancer Other Total
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
A. Unadjusted
<17.5% 20-carbon (n = 508) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
17.5%–18.4% (n = 509) 1.03 (0.71, 1.50) 0.95 (0.53, 1.70) 0.96 (0.54, 1.70) 1.19 (0.54, 2.62) 0.80 (0.48, 1.32) 0.84 (0.49, 1.46) 0.89 (0.65, 1.22)
18.4%–19.1% (n = 502) 0.92 (0.61, 1.39) 0.95 (0.52, 1.71) 0.78 (0.41, 1.49) 0.83 (0.31, 2.20) 0.90 (0.53, 1.53) 1.59 (0.94, 2.67) 1.16 (0.83, 1.63)
19.1%–19.9% (n = 502) 0.88 (0.58, 1.33) 1.22 (0.71, 2.09) 0.63 (0.32, 1.24) 1.24 (0.55, 2.80) 0.87 (0.52, 1.46) 1.19 (0.67, 2.09) 1.02 (0.73, 1.42)
>19.9% (n = 479) 1.03 (0.70, 1.52) 0.99)0.55, 1.77) 1.04 (0.59, 1.82) 0.77 (0.37, 1.60) 0.92 (0.55, 1.53) 1.14 (0.65, 2.01) 0.95 (0.69, 1.33)
p-value for linear trend 0.82 0.71 0.68 0.54 0.83 0.32 0.90
B. Adjusted for demos
<17.5% 20-carbon (n = 508) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
17.5%–18.4% (n = 509) 1.10 (0.74, 1.65) 0.96 (0.52, 1.75) 1.19 (0.62, 2.30) 1.58 (0.61, 4.11) 0.84 (0.49, 1.42) 0.86 (0.45, 1.67) 1.01 (0.71, 1.44)
18.4%–19.1% (n = 502) 0.96 (0.61, 1.51) 0.93 (0.49, 1.79) 1.09 (0.54, 2.21) 1.23 (0.38, 4.02) 0.98 (0.53, 1.81) 1.91 (1.08, 3.36) * 1.33 (0.92, 1.92)
19.1%–19.9% (n = 502) 1.04 (0.67, 1.61) 1.29 (0.71, 2.36) 0.88 (0.43, 1.80) 1.98 (0.75, 5.19) 1.02 (0.58 1.78) 1.45 (0.77, 2.70) 1.27 (0.88, 1.81)
>19.9% (n = 479) 1.21 (0.78, 1.88) 1.06 (0.56, 2.02) 1.48 (0.75, 2.92) 1.19 (0.44, 3.21) 1.21 (0.69, 2.13) 1.40 (0.75, 2.61) 1.19 (0.82, 1.73)
p-value for linear trend 0.52 0.52 0.53 0.55 0.42 0.11 0.16
C. Adjusted for demos and O3I
<17.5% 20-carbon (n = 508) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
17.5%–18.4% (n = 509) 0.97 (0.65, 1.46) 0.84 (0.46, 1.51) 0.96 (0.50, 1.86) 1.30 (0.47, 3.61) 0.84 (0.49, 1.44) 0.77 (0.40, 1.51) 0.94 (0.65, 1.36)
18.4%–19.1% (n = 502) 0.81 (0.51, 1.30) 0.77 (0.39, 1.51) 0.82 (0.39, 1.72) 0.99 (0.28, 3.55) 0.99 (0.52, 1.88) 1.62 (0.92, 2.86) 1.19 (0.81, 1.75)
19.1%–19.9% (n = 502) 0.85 (0.53, 1.34) 1.03 (0.55, 1.91) 0.61 (0.28, 1.33) 1.55 (0.56, 4.30) 1.03 (0.57, 1.86) 1.17 (0.60, 2.27) 1.12 (0.76, 1.65)
>19.9% (n = 479) 0.97 (0.60, 1.56) 0.82 (0.41, 1.65) 1.03 (0.49, 2.15) 0.85 (0.27, 2.72) 1.23 (0.67, 2.26) 1.12 (0.58, 2.16) 1.04 (0.70, 1.56)
p-value for linear trend 0.72 0.87 0.91 0.89 0.42 0.44 0.58
p-value for omega-3 0.011 * 0.039 * 0.009 ** 0.13 0.87 0.03 * 0.04 *
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; O3I, Omega-3 Index. * p < 0.05; ** p < 0.01. All significant hazard ratios/p-values are
shown in bold italics. A. Unadjusted model, B. Adjusted for all variables in Table 1 except history of CVD, C. Adjusted for omega-3 index and all variables in Table 1 except history of CVD.
Quintiles for 18-carbon n-6 fatty acids are shown in the left-most column. For example, 17.5%–18.4% means that the second quintile for RBC 20-carbon n-6 fatty acids are individuals for
whom between 17.5 and 18.4% of all RBC fatty acids are 20-carbon n-6 fatty acids.
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Table 2. Cont.
(c)
Total Events Mortality
CVD CHD Stroke CVD Cancer Other Total
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
A. Unadjusted
<3.6% 22-carbon (n = 508) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
3.6%–4.3% (n = 508) 1.37 (0.88, 2.12) 1.24 (0.63, 2.43) 1.25 (0.62, 2.53) 0.93 (0.42, 2.03) 0.86 (0.52, 1.42) 1.11 (0.64, 1.93) 0.96 (0.69, 1.31)
4.3%–4.7% (n = 500) 1.73 (1.14, 2.62) ** 2.43 (1.34, 4.42) ** 1.36 (0.71, 2.61) 0.81 (0.35, 1.83) 0.65 (0.38, 1.13) 0.96 (0.53, 1.73) 0.80 (0.57, 1.13)
4.7%–5.3% (n = 509) 1.46 (0.96, 2.22) 1.61 (0.86, 3.03) 1.58 (0.83, 2.98) 1.16 (0.54, 2.49) 0.78 (0.46, 1.31) 1.27 (0.72, 2.26) 1.04 (0.75, 1.45)
>5.3% (n = 469) 1.73 (1.12, 2.68) * 2.25 (1.22, 4.16) ** 1.48 (0.74, 2.98) 0.63 (0.24, 1.67) 1.18 (0.71, 1.95) 1.43 (0.82, 2.50) 1.10 (0.77, 1.56)
p-value for linear trend 0.02 * 0.006 ** 0.18 0.57 0.74 0.17 0.48
B. Adjusted for demos
<3.6% 22-carbon (n = 508) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
3.6%–4.3% (n = 508) 1.20 (0.75, 1.93) 1.05 (0.50, 2.20) 1.39 (0.62, 3.13) 0.83 (0.28, 2.41) 0.94 (0.56, 1.60) 1.06 (0.60, 1.88) 1.01 (0.71, 1.44)
4.3%–4.7% (n = 500) 1.74 (1.13, 2.67) * 2.38 (1.26,4.48) ** 1.73 (0.85, 3.55) 0.65 (0.26, 1.62) 0.74 (0.41, 1.32) 0.85 (0.41, 1.76) 0.85 (0.58, 1.25)
4.7%–5.3% (n = 509) 1.36 (0.87, 2.13) 1.51 (0.76, 2.99) 1.89 (0.92, 3.87) 1.28 (0.62, 2.62) 0.74 (0.41, 1.31) 1.31 (0.68, 2.51) 1.11 (0.78, 1.59)
>5.3% (n = 469) 1.66 (1.02, 2.69) * 1.91 (0.95, 3.83) 2.01 (0.92, 4.42) 0.60 (0.18, 2.01) 1.21 (0.71, 2.07) 1.53 (0.85, 2.74) 1.17 (0.81, 1.71)
p-value for linear trend 0.031 * 0.04 * 0.04 * 0.80 0.91 0.10 0.32
C. Adjusted for demos and O3I
<3.6% 22-carbon (n = 508) 1.0 1.0 1.0 1.0 1.0 1.0 1.0
3.6%–4.3% (n = 508) 1.11 (0.69, 1.79) 0.99 (0.48, 2.05) 1.20 (0.53, 2.69) 0.62 (0.20, 1.95) 0.93 (0.54, 1.60) 0.89 (0.48, 1.63) 0.89 (0.62, 1.29)
4.3%–4.7% (n = 500) 1.52 (0.96, 2.39) 2.09 (1.07, 4.06) * 1.35 (0.65, 2.80) 0.42 (0.17, 1.06) 0.72 (0.38, 1.36) 0.67 (0.32, 1.42) 0.69 (0.45, 1.05)
4.7%–5.3% (n = 509) 1.14 (0.70, 1.86) 1.25 (0.60, 2.62) 1.37 (0.64, 2.97) 0.69 (0.27, 1.76) 0.71 (0.38, 1.34) 0.97 (0.48, 1.94) 0.87 (0.58, 1.30)
>5.3% (n = 469) 1.33 (0.77, 2.28) 1.51 (0.69, 3.30) 1.38 (0.60, 3.18) 0.30 (0.07, 1.26) 1.15 (0.57, 2.33) 0.98 (0.48, 1.98) 0.85 (0.54, 1.34)
p-value for linear trend 0.42 0.34 0.44 0.14 0.97 0.88 0.57
p-value for omega-3 0.09 0.22 0.049 * 0.034 * 0.92 0.03 * 0.021 *
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; O3I, Omega-3 Index. * p < 0.05; ** p < 0.01. All significant hazard ratios/p-values are
shown in bold italics. A. Unadjusted model, B. Adjusted for all variables in Table 1 except history of CVD, C. Adjusted for omega-3 index and all variables in Table 1 except history of CVD.
Quintiles for 18-carbon n-6 fatty acids are shown in the left-most column. For example, 3.6%–4.3% means that the second quintile for RBC 22-carbon n-6 fatty acids are individuals for
whom between 3.6 and 4.3% of all RBC fatty acids are 22-carbon n-6 fatty acids.
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3.3. Additional Fatty Acid Analyses
Supplemental Table S3a–g illustrate parallel analyses for each of the seven individual n-6 FAs.
In short, these analyses follow what was observed for the classes of FAs. Namely, few associations
were observed between the individual FAs and either cardiovascular events or mortality and what
few associations were observed in unadjusted models tended to become non-significant in models
that adjusted for demographic covariates. One exception was the positive association between ESA
(C20:2n6) and all-cause mortality, a relationship which remained even after adjusting for the omega-3
index (Table S3c). Other exceptions were the positive associations between DTA (C22:4n6) and stroke,
and the positive associations between DPA (C22:5n6) and all-cause mortality and non-CVD/non-cancer
mortality, though these associations all became non-significant after adjusting for the omega-3 index
(Table S3f–g). An analysis on the sum of all seven omega-6 FAs identified no significant associations
after adjusting for the omega-3 index.
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In short, these analyses follow what was observed for the classes of FAs. Namely, few associations 
were observed between the individual FAs and either cardiovascular events or mortality and what 
Figure 1. (a) Hazard ratios for total cardiovascular (CVD) risk by n-6 FAs and the omega-3 index.
Figure 1a illustrates the associations between n-6 or n-3 fatty acids and total CVD risk. Bar heights
are hazard ratios with 95% confidence intervals provided for each hazard ratio. Hazard ratios are
provided for each quintile are all relative to the risk within the lowest quintile. Statistically significant
HRs at the 0.05 level are denoted with asterisks. Hazard ratios depicted in this figure are from models
adjusting for all demographic variables in Table 1, but do not adjust for the omega-3 index and/or
other omega-6 FAs. There is no significant linear trend for the 18-carbon n-6 FAs (p = 0.68) or the
20-carbon n-6 FAs (p = 0.52), while the 22-carbon n-6 FAs (p = 0.031) and the omega-3 index (p = 0.008)
both have significant linear trends across the 5 quintile groups (see Table 2a–c for additional details).
Finally, we note that, as shown in Table 2c, both linear associations as well as all individual quintile
group associations become non-significant (p > 0.05) for both the omega-3 index and 22 carbon n-6 FAs
when both are simultaneously entered into the statistical model. (b) Hazard ratios for total mortality
(CVD) risk by n-6 FAs and the omega-3 index. Figure 1b illustrates the associations between n-6 or n-3
fatty acids and Total mortality. Bar heights are hazard ratios with 95% confidence intervals provided
for each hazard ratio. Hazard ratios are provided for each quintile are all relative to the risk within the
lowest quintile. Statistically significant HRs at the 0.05 level are denoted with asterisks. Hazard ratios
depicted in this figure are from models adjusting for all demographic variables in Table 1, but do not
adjust for the omega-3 index and/or other omega-6 FAs. There is no significant linear trend for the 18
carbon n-6 FAs (p = 0.69), the 20 carbon n-6 FAs (p = 0.16) and the 22 carbon n-6 FAs (p = 0.32), while,
the omega-3 index (p = 0.02) has a significant linear trend across the 5 quintile gro ps. Finally, we
note that, as sh wn in Table 2c, linear asso iations s well as all individual quintile gro p associations
become non-significant (p > 0.05) for all n-6 fatty acids when adjusting for the omega-3 ind x, while the
omega-3 index remains significant (p < 0.05) in all models.
4. Discussion
In this study of participants in the Framingham Offspring study, the n-6 PUFAs were generally
unrelated with vital status, especially in fully adjusted models accounting for subject characteristics
and the omega-3 index. The only exception was for EDA which was directly related with risk all-cause
mortality. The omega-3 index was inversely associated with most of the outcomes examined here
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even after adjustment for the n-6 FAs, whether in the full aggregate, the carbon-chain groups, or the
individual n-6 FAs.
Delgado et al. recently reported the relations between red blood cell (RBC) n-6 FA levels and
risk for death from all causes [22]. Using data from 3259 patients undergoing diagnostic coronary
artery catheterization and followed for 10 years, these investigators found that RBC levels of n-6 FAs
were inversely related with risk for death. However, a more granular examination revealed widely
varying associations with n-6 FAs depending on chain length. The 18-carbon species (LA and GLA)
were inversely associated with death, those with 20 carbons (AA and DGLA) were largely unrelated
with risk, and those with 22 carbons (ADA and DPAn-6) were directly related with risk. A case-control
study using RBC FA profiles from acute coronary syndrome patients found that a suite of 10 RBC
FAs was able to predict case status better than the classical risk factors included in the Framingham
Risk Score [23]. In that study, LA, AA, and GLA were predictors of lower risk for coronary disease,
whereas EDA was associated with higher risk. In yet another study, RBC both EPA and DPAn-6 added
independent predictive power to a standard algorithm used to predict risk for death in post myocardial
infarction patients [24]. All of these studies suggest that n-6 FAs are not all created equal, and that
to speak of them as a monolithic class of FAs with similar biochemical functions and physiological
roles is probably incorrect. In this study, we further illustrated a widely varying correlation structure
between n-3 FAs and n-6 FAs, as well as within the n-6 FAs, further supporting the argument that not
each n-6 FA may have its own unique role to play in metabolism. However, one important trend worth
noting is that, for 22 carbon FAs, associations with cardiovascular outcomes which were significant
even after adjusting for demographic variables, became non-significant after adjusting for n-3 FAs.
In these models (Table2c, fully adjusted model), n-3 FAs were significant, suggesting that the initial
n-6 associations with cardiovascular outcomes were better explained by variation in n-3 FAs. Further
work is needed to better understand the role of the full profile of fatty acids on disease risk.
The EDA finding in the present study was somewhat unexpected. EDA levels were adversely
associated risk for acute coronary syndromes in a case-control study from Kansas City [23]. On the
other hand, serum EDA levels were recently reported to be reduced in patients with inflammatory
bowel disease [25], and in a large prospective study of plasma phospholipid FAs and risk for type 2
diabetes, EDA was inversely associated with incident disease [26]. These findings—along with those
of the present study—would suggest that EDA participates in some manner in pathophysiology of
these conditions. EDA is an elongation product of LA (C18 to C20, both with 2 double bonds), and on
the biosynthetic path to DGLA and AA. These latter two n-6 FAs serve as substrates for the production
of a wide variety of active metabolites called oxylipins [27], but whether the beneficial/harmful effects
of EDA (if they indeed exist) are mediated by oxylipin metabolism is unknown. Complicating these
inconsistent observations is the fact that levels of EDA in these subjects were very low, averaging only
about 0.25% of total RBC FAs. Consequently, the ultimate meaning and impact of EDA in biology
is unclear.
Strengths and Limitations
Strengths of this study include the large sample size and number of events, the unambiguous
nature of the primary endpoint, the inclusion of community dwellers (instead of a patient population),
and the use of an objective biomarker of PUFA exposure with low biological variability [28].
The previous detection of clear inverse relations between the omega-3 index and outcomes in this same
cohort suggests that our failure to see associations with the n-6 FAs was not due to a lack of power,
but a lack of effect. The assessment of PUFA exposure at only one time point cannot capture PUFA
status changes throughout follow-up. Finally, the inability to rule out the possibility of residual or
unmeasured confounding also precludes inferences about causality [29].
In conclusion, we found no meaningful relationship between RBC levels of n-6 PUFAs and risk
for CVD or total mortality. Importantly, after adjustment for covariates, there was no increase in risk
for adverse outcomes with higher n-6 PUFA levels, with the possible exception of EDA. These findings,
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in the context of the totality of available evidence on this subject, provide no support for a harmful
role of n-6 PUFAs in these important clinical outcomes.
5. Conclusions
Higher circulating levels of marine n-3 FA levels are associated with reduced risk for incident
CVD and ischemic stroke and for death from CHD and all-causes; however, in the same sample little
evidence exists for association with n-6 FAs. Further work is needed to identify a full profile of FAs
associated with cardiovascular risk and mortality.
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Index (5-groups), Table S3b: Gamma-linolenic Acid, Table S3c: Eicosadienoic Acid, Table S3d: Eicosatrienoic Acid,
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AA arachidonic acid
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DHA docosahexaenoic acid
DPA n-6 docosapentaenoic acid
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